| scholarly article | Q13442814 |
| P2093 | author name string | Giuseppe Giannini | |
| Annamaria Naggi | |||
| Benito Casu | |||
| Giangiacomo Torri | |||
| Claudio Pisano | |||
| Israel Vlodavsky | |||
| Marta Perez | |||
| Sergio Penco | |||
| Rivka Ishai-Michaeli | |||
| Giuseppe Cassinelli | |||
| P2860 | cites work | Human heparanase. Purification, characterization, cloning, and expression | Q22003728 |
| Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis | Q22010222 | ||
| Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization | Q24290400 | ||
| Structural recognition by recombinant human heparanase that plays critical roles in tumor metastasis. Hierarchical sulfate groups with different effects and the essential target disulfated trisaccharide sequence | Q24306149 | ||
| Heterodimer formation is essential for heparanase enzymatic activity | Q24316892 | ||
| Structure of a heparin-linked biologically active dimer of fibroblast growth factor | Q27760195 | ||
| Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis | Q28138868 | ||
| Identification of active-site residues of the pro-metastatic endoglycosidase heparanase | Q28140703 | ||
| Substrate specificity of heparanases from human hepatoma and platelets | Q28276774 | ||
| Heparanases and tumor metastasis | Q28294717 | ||
| Functions of cell surface heparan sulfate proteoglycans | Q29618521 | ||
| Molecular weight determination of heparin and dermatan sulfate by size exclusion chromatography with a triple detector array | Q31139647 | ||
| Heparanase, a potential regulator of cell-matrix interactions | Q33984496 | ||
| Conformation and dynamics of heparin and heparan sulfate | Q34087654 | ||
| Structure and biological interactions of heparin and heparan sulfate | Q34523315 | ||
| Proteoglycans: structures and interactions | Q37285263 | ||
| Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound | Q37365612 | ||
| Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells | Q38331586 | ||
| Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors | Q38363705 | ||
| Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans | Q39579344 | ||
| Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol | Q39831228 | ||
| Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. | Q40464583 | ||
| Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis | Q40521421 | ||
| Increased expression of heparanase in puromycin aminonucleoside nephrosis | Q40778136 | ||
| Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells | Q41768277 | ||
| The N-acetylation and estimation of hexosamines | Q42177598 | ||
| Undersulfated and glycol-split heparins endowed with antiangiogenic activity | Q44754685 | ||
| Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells | Q44984384 | ||
| A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer | Q45013436 | ||
| Studies on heparin degradation. I. Preparation of ( 35 S) sulphamate derivatives for studies on heparin degrading enzymes of mammalian origin | Q45184949 | ||
| Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist | Q47403396 | ||
| Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix | Q47416115 | ||
| 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity | Q48356098 | ||
| 'Heparin'--from anticoagulant drug into the new biology | Q48773643 | ||
| Novel drug development opportunities for heparin. | Q54153135 | ||
| Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. | Q54705410 | ||
| Heparanase expression in hepatocellular carcinoma and the cirrhotic liver | Q57767843 | ||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| P304 | page(s) | 12103-12113 | |
| P577 | publication date | 2005-01-12 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting | |
| P478 | volume | 280 |
| Q39254044 | A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. |
| Q37740310 | Antimetastatic activities of heparins and modified heparins. Experimental evidence. |
| Q37565298 | Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases |
| Q33744134 | Assessment of Heparanase-Mediated Angiogenesis Using Microvascular Endothelial Cells: Identification of λ-Carrageenan Derivative as a Potent Anti Angiogenic Agent |
| Q89497261 | Cancer Metastasis: The Role of the Extracellular Matrix and the Heparan Sulfate Proteoglycan Perlecan |
| Q35810537 | Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins |
| Q38333539 | Computational analyses of the catalytic and heparin-binding sites and their interactions with glycosaminoglycans in glycoside hydrolase family 79 endo-β-D-glucuronidase (heparanase). |
| Q88658608 | Design, synthesis, and evaluation of heparan sulfate mimicking glycopolymers for inhibiting heparanase activity |
| Q41900600 | Effect of non-anticoagulant N-desulfated heparin on basic fibroblast growth factor expression, angiogenesis, and metastasis of gastric carcinoma in vitro and in vivo |
| Q33269554 | Effect of non-anticoagulant N-desulfated heparin on expression of vascular endothelial growth factor, angiogenesis and metastasis of orthotopic implantation of human gastric carcinoma |
| Q91798106 | Forty Years of Basic and Translational Heparanase Research |
| Q37623543 | Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. |
| Q98177430 | Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease |
| Q89943975 | Glycosaminoglycans as Tools to Decipher the Platelet Tumor Cell Interaction: A Focus on P-Selectin |
| Q58585910 | Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal Activity |
| Q38116039 | Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses |
| Q37983752 | Heparanase enzyme in chronic inflammatory bowel disease and colon cancer |
| Q28303555 | Heparanase in glomerular diseases |
| Q38080632 | Heparanase in inflammation and inflammation-associated cancer |
| Q56894096 | Heparanase induces a differential loss of heparan sulphate domains in overt diabetic nephropathy |
| Q39782778 | Heparanase is essential for the development of diabetic nephropathy in mice. |
| Q33834001 | Heparanase levels are elevated in the urine and plasma of type 2 diabetes patients and associate with blood glucose levels |
| Q35023917 | Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer |
| Q44606727 | Heparanase procoagulant effects and inhibition by heparins |
| Q35587352 | Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. |
| Q28511958 | Heparanase regulates murine hair growth |
| Q35669031 | Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: a mechanism possibly involved in hereditary multiple exostoses |
| Q33833954 | Heparanase upregulates Th2 cytokines, ameliorating experimental autoimmune encephalitis |
| Q37006624 | Heparanase, heparin and the coagulation system in cancer progression |
| Q36999958 | Heparanase-A Link between Coagulation, Angiogenesis, and Cancer |
| Q33924987 | Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells |
| Q35182839 | Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype |
| Q60931211 | Heparanase: A Multitasking Protein Involved in Extracellular Matrix (ECM) Remodeling and Intracellular Events |
| Q36088435 | Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Injury |
| Q42587945 | Heparanase: From basic research to therapeutic applications in cancer and inflammation |
| Q38801721 | Heparanase: a rainbow pharmacological target associated to multiple pathologies including rare diseases |
| Q36752653 | Heparanase: a target for drug discovery in cancer and inflammation |
| Q37371146 | Heparanase: busy at the cell surface |
| Q47159791 | Heparin Mimetics: Their Therapeutic Potential. |
| Q37736668 | Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer |
| Q38418286 | Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. |
| Q38639564 | High Sulfation and a High Molecular Weight Are Important for Anti-hepcidin Activity of Heparin. |
| Q48005441 | Identification of Heparin Modifications and Polysaccharide Inhibitors of Plasmodium falciparum Merozoite Invasion That Have Potential for Novel Drug Development |
| Q28083753 | Impact of heparanase on renal fibrosis |
| Q39958338 | Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells |
| Q79272921 | Increased expression of heparanase in overt diabetic nephropathy |
| Q33860126 | Increased migration of antigen presenting cells to newly-formed lymphatic vessels in transplanted kidneys by glycol-split heparin |
| Q57563789 | Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides |
| Q27025052 | Involvement of heparanase in atherosclerosis and other vessel wall pathologies |
| Q40707545 | Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase. |
| Q38812867 | Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms |
| Q37818236 | Macromolecules as taxane delivery systems. |
| Q36542354 | Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression |
| Q48089220 | Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat |
| Q90680589 | Modulating Heparanase Activity: Tuning Sulfation Pattern and Glycosidic Linkage of Oligosaccharides |
| Q36847852 | Modulation of hepcidin to treat iron deregulation: potential clinical applications |
| Q38152204 | Molecular engineering of glycosaminoglycan chemistry for biomolecule delivery |
| Q28475274 | Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases |
| Q91798207 | Non-Anticoagulant Heparins as Heparanase Inhibitors |
| Q37379726 | Non-anticoagulant heparins and inhibition of cancer |
| Q38855728 | Old and new applications of non-anticoagulant heparin |
| Q26823840 | Pathophysiology of heparan sulphate: many diseases, few drugs |
| Q52560290 | Phase I study of the heparanase inhibitor Roneparstat: an innovative approach for multiple myeloma therapy. |
| Q34664539 | Pre-clinical and clinical significance of heparanase in Ewing's sarcoma. |
| Q38319635 | Profiling glycol-split heparins by high-performance liquid chromatography/mass spectrometry analysis of their heparinase-generated oligosaccharides |
| Q34398151 | Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis |
| Q49556347 | Remembering Professor Benito Casu (1927-2016). |
| Q34557376 | Role of endothelial heparanase in delayed-type hypersensitivity |
| Q34762351 | Role of heparanase in radiation-enhanced invasiveness of pancreatic carcinoma |
| Q34694466 | SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis |
| Q58759632 | Selective Deletion of Heparan Sulfotransferase Enzyme, Ndst1, in Donor Endothelial and Myeloid Precursor Cells Significantly Decreases Acute Allograft Rejection |
| Q36101233 | Significance of heparanase in cancer and inflammation |
| Q90445879 | Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice |
| Q39033979 | Specific heparanase inhibition reverses glucose-induced mesothelial-to-mesenchymal transition. |
| Q37586232 | Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments |
| Q37008599 | Syndecan-1: a dynamic regulator of the myeloma microenvironment |
| Q47662409 | Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection. |
| Q92137106 | Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds |
| Q39399937 | Targeting heparin and heparan sulfate protein interactions. |
| Q92812032 | The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives |
| Q36936771 | The antineoplastic effect of low-molecular-weight heparins - a literature review |
| Q38605695 | The glycocalyx--linking albuminuria with renal and cardiovascular disease |
| Q38078480 | The heparanase/syndecan-1 axis in cancer: mechanisms and therapies |
| Q36452903 | The potential of heparanase as a therapeutic target in cancer |
| Q35990705 | The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy |
| Q33824982 | Unraveling the specificity of heparanase utilizing synthetic substrates |
| Q33770777 | Versatile role of heparanase in inflammation |
| Q64096287 | λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration |
Search more.